These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17526917

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA, Vazquez J, De Waele J, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ.
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
    Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA, Caspofungin High-Dose Study Group.
    Clin Infect Dis; 2009 Jun 15; 48(12):1676-84. PubMed ID: 19419331
    [Abstract] [Full Text] [Related]

  • 10. [Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections].
    Lichtenstern C, Pratschke J, Schulz U, Schmoeckel M, Knitsch W, Kaskel P, Krobot KJ, Weigand MA, Winkler M.
    Anaesthesist; 2010 Dec 15; 59(12):1083-90. PubMed ID: 21069271
    [Abstract] [Full Text] [Related]

  • 11. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.
    Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA.
    J Antimicrob Chemother; 2004 May 15; 53(5):878-81. PubMed ID: 15044431
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P, Sirohi B, Seibel NL, Hsu JW, Azie N, Wu C, Ruhnke M.
    Mycoses; 2018 May 15; 61(5):331-336. PubMed ID: 29364548
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
    Cornely OA, Marty FM, Stucker F, Pappas PG, Ullmann AJ.
    Mycoses; 2011 Nov 15; 54(6):e838-47. PubMed ID: 21668522
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients.
    Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A.
    J Antimicrob Chemother; 2010 Aug 15; 65(8):1765-70. PubMed ID: 20554567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.